Cardio Diagnostics Holdings, Inc. (CDIO): Revenue

Annual figures by period end, from SEC filings.

$14.8K

Year ended 2025-12-31

$14.4K

Trailing 12 months to 2026-06-30

+149.9%

3-year compound annual growth

2021-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$14.8K	-57.5%	2026-03-13, From 2025-01-01
2024-12-31	$34.9K	+104.5%	2026-03-13, From 2024-01-01
2023-12-31	$17.1K	n/m	2025-03-20, From 2023-01-01
2022-12-31	$950	+5.4%	2024-04-01, From 2022-01-01
2021-12-31	$901	n/a	2023-03-31, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Cardio Diagnostics Holdings, Inc. (CDIO)	2025-12-31	$14.8K	-57.5%
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	$1.54M	-78.0%
Volitionrx Ltd (VNRX)	2025-12-31	$1.73M	+40.0%
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	$4.05M	+115.6%
Biomerica Inc (BMRA)	2026-05-31	$4.45M	-16.2%
Anbio Biotechnology (NNNN)	2025-12-31	$8.65M	+5.6%
Aspira Women's Health Inc. (AWHL)	2025-12-31	$9.22M	+0.4%
Immucell Corp (ICCC)	2025-12-31	$27.64M	+4.3%
Alpha Teknova, Inc. (TKNO)	2025-12-31	$40.52M	+7.4%

Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗